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Background: The objective of this analysis was to assess the effects of edoxaban compared with enoxaparin on key
coagulation biomarkers and present pooled primary efficacy and safety results from phase 3 STARS E-3 and STARS J-V
trials for prevention of venous thromboembolism (VTE) after total knee arthroplasty (TKA) or total hip arthroplasty (THA).
Methods: In the randomized, double-blind, double-dummy, multicenter, STARS E-3 and STARS J-V trials, patients received
edoxaban 30 mg or enoxaparin 2000 IU (20 mg) twice daily for 11 to 14 days. The studies were conducted in Japan and
Taiwan; enoxaparin dosing was based on Japanese label recommendations. The primary efficacy endpoint was incidence
of VTE; the safety endpoint was major or clinically relevant nonmajor (CRNM) bleeding. Blood samples were taken
at presurgical evaluation, pretreatment (postsurgery), predose on day 7, predose on completion of treatment, and
at a follow-up examination 25 to 35 days after the last dose of study drug for D-dimer, prothrombin fragment 1 + 2 (F1+2),
and soluble fibrin monomer complex (SFMC) measurement.
Results: A total of 716 patients enrolled in STARS E-3 and 610 patients enrolled in STARS J-V; 1326 patients overall. This
analysis included 657 patients who received edoxaban 30 mg QD and 650 patients who received enoxaparin 20 mg BID.
Incidence of VTE was 5.1 and 10.7% for edoxaban and enoxaparin, respectively (P <0.001). Incidence of combined major
and CRNM bleeding was 4.6 and 3.7% for edoxaban and enoxaparin, respectively (P = 0.427). On day 7, mean D-dimer
(4.4 vs 5.5 μg/mL), F1+2 (363 vs 463 pmol/L), and SFMC (5.7 vs 6.8 μg/mL) were lower in edoxaban-treated patients
relative to enoxaparin-treated patients, respectively (P <0.0001 for all). At end of treatment, mean D-dimer (5.4 vs 6.
2 μg/mL), F1+2 (292 vs 380 pmol/L), and SFMC (6.2 vs 7.2 μg/mL) were lower in edoxaban-treated patients relative to
enoxaparin-treated patients (P <0.0001 for all).
Conclusions: Edoxaban was superior to enoxaparin in prevention of VTE following TKA and THA, with comparable
rates of bleeding events. Relative to enoxaparin, edoxaban significantly reduced D-dimer, F1+2, and SFMC.
Trial registration: Clintrials.gov NCT01181102 and NCT01181167. Both registered 8/12/2010.
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Patients undergoing orthopedic surgery such as total
knee arthroplasty (TKA) or total hip arthroplasty (THA)
are at high risk for venous thromboembolism (VTE)
[1, 2]. Anticoagulation therapy and/or mechanical
prophylaxis, including compression stockings or inter-
mittent pneumatic compression, are recommended for
prevention of VTE after orthopedic surgery [1, 2]. In
Japan, edoxaban [3], a direct oral anticoagulant (DOAC)
selective inhibitor of activated factor Xa (FXa), and enoxa-
parin [4], an injectable low-molecular-weight heparin
(LMWH), are both indicated for prophylaxis of deep vein
thrombosis (DVT) following TKA, THA, or hip fracture
surgery. The approval of edoxaban for the primary pre-
vention of VTE after lower limb orthopedic surgery was
based on evidence collected during three phase 3 studies
evaluating the safety and efficacy of edoxaban compared
with enoxaparin for prevention of VTE in Japanese or Tai-
wanese patients following TKA [5], THA [6], and hip frac-
ture surgery [7]. In these studies, edoxaban demonstrated
significantly reduced or comparable rates of VTE and
similar rates of bleeding events relative to enoxaparin.
This report presents a post hoc pooled analysis of co-
agulation biomarkers in the TKA/THA studies as well as
pooled results of the primary efficacy (VTE) and safety
(bleeding events) endpoints. Coagulation biomarkers
include D-dimer, prothrombin fragments 1 + 2 (F1+2),
and soluble fibrin monomer complex (SFMC). D-dimer,
which has a high negative predictive value for VTE, is
formed upon cleavage of cross-linked fibrin polymers by
plasmin [8–10]. F1+2 is a marker of thrombin generation
and represents coagulation activity [11]. Fibrin mono-
mers result from cleavage of fibrinogen by thrombin [8].
Soluble fibrin in plasma is also a marker of coagulation
activity and is seen to increase rapidly during and after
hip replacement surgery [12]. Assessment of coagulation
biomarkers can provide information on the effect of
anticoagulants in relation to dose and clinical response.
Methods
Detailed descriptions of the methodology of these trials
are available in the primary publications (STARS E-3 [5]
and STARS J-V [6]). The trial designs for patients under-
going TKA (STARS E-3; NCT01181102) or THA (STARS
J-V; NCT01181167) were similar. In the randomized,
double-blind, double-dummy, multicenter trials, patients
received oral edoxaban 30 mg or edoxaban placebo once
daily within 6 to 24 h after surgery, and subcutaneous
enoxaparin 2000 IU (equivalent to 20 mg) or enoxaparin
placebo twice daily within 24 to 36 h after surgery, each
for 11 to 14 days. Enoxaparin 20 mg is the usual recom-
mended dose for adults in Japan due to the lower body
weight of Japanese patients [13]; standard of care is
administration of enoxaparin 24 to 36 h postsurgery.Concomitant use of anticoagulants, antiplatelet agents,
thrombolytic agents, or other agents that affect
thrombus formation was not allowed from the day of
surgery until 24 h after the final dose of study drug, un-
less treatment of deep vein thrombosis or pulmonary
embolism (PE) was required. Mechanical prophylaxis
(eg, elastic stockings or intermittent pneumatic com-
pression therapy of the foot sole or lower leg and thigh)
was permitted from the day of surgery to venography.
Venography of the operated lower limb in the TKA trial
STARS E-3 and of both lower limbs in the THA trial
STARS J-V was performed within 24 h of the last dose
of study drug or within 96 h in exceptional cases such as
difficulty establishing an intravenous line.
The studies were performed in accordance with the
provisions of the Declaration of Helsinki, Guidelines for
Good Clinical Practice, and other related regulations.
The protocols were approved by institutional review
boards at each study center, and written informed consent
was obtained from all patients prior to randomization.
Patients
Men and women 20 to <85 years of age undergoing uni-
lateral TKA or THA (both excluding revision arthroplasty)
were included. Presurgical exclusion criteria included risk
for bleeding, risk for thromboembolism, previous TKA,
weight <40 kg, severe renal impairment (creatinine clear-
ance <30 mL/min) [14], evidence of hepatic dysfunction
(serum aspartate aminotransferase or serum alanine amino-
transferase levels ≥2 times the upper limit of normal or
total bilirubin ≥1.5 times the upper limit of normal),
previous treatment with edoxaban, and current anti-
thrombotic therapy for another complication. Postsurgical
exclusion criteria included abnormal bleeding from the
puncture site during spinal anesthesia, need for repeat
surgery before the start of study treatment, abnormal or
excessive bleeding experienced during surgery, and inability
to take oral medication.
Assessments
Thromboembolic events included asymptomatic or symp-
tomatic DVT—confirmed by venography at the end of
study treatment—and symptomatic and diagnosed PE.
Additional imaging techniques used to confirm suspected
DVT or PE included ultrasonography, computerized tom-
ography scanning, pulmonary scintigraphy, or pulmonary
arteriography.
Major bleeding was defined as fatal bleeding; clinically
overt bleeding accompanied by a decrease in hemoglobin
of >2 g/dL or requiring transfusion with >800 mL of
blood; retroperitoneal, intracranial, intraocular, or intra-
thecal bleeding; or bleeding requiring repeat surgery.
Clinically relevant nonmajor (CRNM) bleeding was de-
fined as bleeding that did not meet the criteria for major
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diameter, epistaxis or gingival bleeding in the absence of
external factors lasting ≥5 min, gastrointestinal bleeding,
gross hematuria persistent after 24 h of onset, or any other
bleeding deemed clinically significant by the investigator.
Minor bleeding was any bleeding event that was not
considered a major or CRNM bleeding event. Thrombo-
embolic events were assessed by the blinded Thrombo-
embolic Event Assessment Committee and bleeding events
by the Bleeding Event Assessment Committee.
Blood sampling was performed at presurgical evalu-
ation, pretreatment (postsurgery), predose on day 7,
predose on completion of treatment, and at a follow-
up examination 25 to 35 days after the last dose of
study drug. All biomarker assessments for D-dimer,
F1+2, and SFMC were performed and measured at a cen-
tral laboratory (SRL Inc., Tokyo, Japan). D-dimer was
measured by a latex agglutination assay using the LATE-
CLE D-dimer test kit (Kainos Laboratories, Inc., Tokyo,
Japan; upper limit of detection, 1.0 μg/mL); data were
expressed as D-dimer units. Assessment of F1+2 was per-
formed via ELISA (Fibinostika, Organon Teknika BV,
The Netherlands; normal detection range 69–229 pmol/L)
[15] and assessment of SFMC was performed via a latex
immunoturbidimetric assay (upper limit of detection,
6.1 μg/mL) [16].Fig. 1 Distribution of patients in the pooled data analyses. aThe safety ana
posttreatment safety data, and did not have significant GCP violations. bTh
and excluded patients with significant GCP violations or with inadequate ven
categories were counted once for each category. dThe per-protocol set includ
or exclusion criteria, violation of rules for prohibited concomitant drugs/treatm
FAS = full analysis set; THA = total hip arthroplasty; TKA = total knee arthroplasTreatment compliance was assessed by clinical inter-
view with patients and by remaining drugs collected.
Statistical analysis
The primary efficacy endpoint—the proportion of pa-
tients who experienced at least 1 thromboembolic event
from the start of treatment to venography—was assessed
in the full analysis set of patients, those who received ≥1
dose of study drug and who underwent interpretable
venography. Baseline data and safety results were ana-
lyzed in the safety set—patients who received ≥1 dose of
study drug and had safety data collected after the start
of treatment. Biomarker results were analyzed in the
pharmacodynamic set—patients who received ≥1 dose of
study drug, had no protocol violations, had compliance
rates of ≥80%, and had ≥1 biomarker measurement (Fig. 1).
The number of VTE events and number of bleeding
events across the 2 trials were added. The Farrington-
Manning method [17] was used to derive the difference
in VTE incidence. The SCORE method [18] was used to
calculate 95% confidence intervals (CIs) for both VTE
and bleeding events. For analysis of coagulation bio-
markers, summary statistics were calculated by group
and time.
Paired comparisons between groups were performed
using chi squared or Wilcoxon rank sum testing with alysis set included all enrolled patients who received study drug, had
e full analysis set included all patients receiving ≥1 dose of study drug
ography. cMultiple answers were allowed; patients falling under multiple
ed patients in the FAS and excluded patients with violations of inclusion
ent, or <80% compliance with study drug. GCP = good clinical practice;
ty
Fig. 2 Primary efficacy endpoint – incidence of VTE. aChi square test.
VTE = venous thromboembolism
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ducted as 2-sided tests.
Results
Patients
There were no significant differences in baseline charac-
teristics between the combined treatment groups from
the 2 trials (Table 1). Overall, patients were predomin-
antly women (83%) of a mean age of 68 years. The pri-
mary disease was most frequently osteoarthritis (88%). A
total of 1326 patients were enrolled; this analysis in-
cluded 657 patients who received edoxaban 30 mg once
daily and 650 patients who received enoxaparin 20 mg
twice daily. Patient disposition was similar between the 2
trials (Fig. 1).
Primary efficacy endpoint
The composite of asymptomatic DVT and symptomatic
DVT or PE occurred in 28 of 554 patients who received
edoxaban (5.1%) and 58 of 543 patients who received
enoxaparin (10.7%), P <0.001 (Fig. 2). Thromboembolic
events were primarily asymptomatic DVT.
Biomarkers
Plasma levels of the coagulation biomarker D-dimer are
shown in Fig. 3a and Table 2. Mean D-dimer concentra-
tions substantially increased after surgery but before treat-
ment. After treatment, mean D-dimer levels (standard
deviation [SD]) decreased significantly more in the
edoxaban-treated than the enoxaparin-treated patients,
respectively, both on day 7 (4.4 [2.1] vs 5.5 [2.6] μg/mL)
and at the end of treatment (days 11–14) (5.4 [2.5] vs 6.2
[3.1] μg/mL), P <0.0001 for both. Median values and








Female, n (%) 552 (84.0) 527 (81.1) 0.161a
Age, years, mean
(min–max)
68.3 (36–84) 68.1 (24–84) 0.760b
Body weight, kg, mean
(min–max)
58.7 (40–124) 58.8 (40–98) 0.848b
Creatinine clearance,
mL/min, mean (min–max)
82.1 (30.6–242.9) 81.7 (31.0–209.7) 0.804b
Primary disease, n (%)
Osteoarthritis 582 (88.6) 563 (86.6) 0.270c
Rheumatoid arthritis 42 (6.4) 46 (7.1)
Other 35 (5.0) 41 (6.3)
BID twice daily, QD once daily
aChi square test
bt test
cWilcoxon testMean F1+2 concentrations increased after surgery and
decreased following treatment with edoxaban or enoxa-
parin. The observed decrease in F1+2 following edoxaban
treatment was larger relative to the decrease observed
with enoxaparin treatment (Fig. 3b and Table 2). The
mean F1+2 concentrations (SD) in edoxaban-treated and
enoxaparin-treated patients, respectively, on day 7 of
treatment were 363 (164) vs 463 (186) pmol/L and at
the end of treatment were 292 (168) vs 380 (174) pmol/L,
P <0.0001 for both. Median values and ranges are pro-
vided in Additional file 1: Table S1.
Mean SFMC concentrations rose after surgery and
showed a larger decrease following edoxaban treatment
relative to enoxaparin treatment (Fig. 3c and Table 2).
The mean SFMC concentrations (SD) in edoxaban and
enoxaparin patients, respectively, on day 7 were 5.7
(9.8) vs 6.8 (14.0) μg/mL and at the end of treatment
were 6.2 (10.7) vs 7.2 (11.8), P <0.0001 for both.
Median values and ranges are provided in Additional
file 1: Table S1.
Assessment of plasma concentrations of biomarkers
was performed in patients stratified by the presence or
absence of VTE and the presence or absence of major
or CRNM bleeding. Values followed a similar trend for
patients with and without VTE and for edoxaban and
enoxaparin treatment for D-dimer and F1+2 (Table 3).
Values for SFMC were similar between edoxaban and
enoxaparin treatments and were numerically elevated
for patients with VTE relative to those who did not
have VTE. Values for D-dimer, F1+2, and SFMC followed a
similar trend for patients with and without CRNM and for
treatment with edoxaban and enoxaparin (Table 4).
Safety
There were no significant differences in the incidence of
bleeding events during the trial between groups treated
Fig. 3 Levels of coagulation biomarkers. a D-dimer; b Prothrombin fragments 1 + 2 (F1+2); c Soluble fibrin monomer complex (SFMC). Open circles
mark mean; horizontal lines indicate median; boxes represent 25–75%; capped lines represent 10 and 90%; * = P <0.001 (Wilcoxon test)
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CRNM bleeding events occurred in 4.6% of edoxaban-
treated and 3.7% of enoxaparin-treated patients (P = 0.427).
The incidence of adverse events (AEs) was slightly lower in
the edoxaban group (66%) than the enoxaparin group
(75%). There were no differences in the frequency of
serious AEs between the treatment groups [5, 6].
Discussion
The risk of VTE increases after knee or hip arthroplasty
[1, 2]. As shown in this pooled analysis of two phase 3trials 11 to 14 days after surgery for TKA or THA, the
incidence of VTE was significantly lower in patients ad-
ministered once-daily oral edoxaban 30 mg (5.1%) than
in those receiving twice-daily subcutaneous enoxaparin
20 mg (10.7%), P <0.001. Coagulation biomarkers D-
dimer, F1+2, and SFMC each increased immediately after
surgery. Over the course of 11 to 14 days, levels of the
coagulation biomarkers were significantly lower after
treatment with the DOAC edoxaban relative to the
LMWH enoxaparin. In contrast, the frequency of bleeding
events in the pooled results did not significantly differ.
Table 2 Mean plasma concentrations of coagulation biomarkers at various time points after total knee or total hip arthroplasty
Preoperation Pretreatment Day 7a End of treatment (days 11–14)a
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
D-dimer (μg/mL) Edoxaban 535 0.73 (0.82) 535 9.42 (12.56) 532 4.43b (2.08) 528 5.37b (2.52)
Enoxaparin 527 0.78 (0.96) 527 10.92 (16.23) 480 5.53 (2.56) 472 6.23 (3.12)
F1+2 (pmol/L) Edoxaban 535 273.9 (150.6) 535 479.7 (741.8) 532 362.8
b (164.2) 528 292.1b (167.6)
Enoxaparin 527 277.8 (160.9) 527 633.2 (3234.9) 480 463.3 (185.6) 472 379.6 (174.4)
SFMC (μg/mL) Edoxaban 535 5.62 (17.86) 535 32.25 (40.47) 532 5.71b (9.76) 528 6.15b (10.72)
Enoxaparin 527 4.81 (8.42) 527 34.72 (45.62) 480 6.82 (13.99) 472 7.23 (11.78)
F1+2 thrombin fragments 1 + 2, SD standard deviation, SFMC soluble fibrin monomer complex
aPredose
bP vs enoxaparin <0.0001 (Wilcoxon test)
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with the Japanese standard of care for enoxaparin.
Japanese patients typically have a lower body weight
relative to their Western counterparts. Although the
dose of enoxaparin used was low (2000 IU, twice daily),
this is the recommended dose specific to Japan for preven-
tion of VTE [4]. Prophylactic, subcutaneous enoxaparin
doses of 40 mg once daily or 30 mg twice daily in males
weighing >57 kg are associated with increased enoxaparin
exposure and increased bleeding risk. Administration of
LMWH 2 to 4 h postoperatively has been associated with
higher rates of major bleeding relative to administration at
12 to 48 h postoperatively [19]. The Japanese standard of
care calls for initiation of enoxaparin 24 to 36 h following
surgery.Table 3 Mean plasma concentrations of coagulation biomarkers at
patients with and without VTE
Preoperation Pretreatmen
n Mean (SD) n Mea
Patients without VTE
D-dimer (μg/mL) Edoxaban 526 0.73 (0.84) 526 9.33
Enoxaparin 485 0.77 (0.94) 485 10.2
F1+2 (pmol/L) Edoxaban 526 273.6 (150.3) 526 478
Enoxaparin 485 273.9 (139.3) 485 614
SFMC (μg/mL) Edoxaban 526 5.38 (17.34) 526 31.2
Enoxaparin 485 4.33 (6.04) 485 31.8
Patients with VTE
D-dimer (μg/mL) Edoxaban 28 0.75 (0.86) 28 8.40
Enoxaparin 58 0.90 (0.97) 58 16.9
F1+2 (pmol/L) Edoxaban 28 258.4 (117.4) 28 483
Enoxaparin 58 309.8 (273.2) 58 824
SFMC (μg/mL) Edoxaban 28 8.90 (21.23) 28 52.1
Enoxaparin 58 8.36 (18.17) 58 63.6
F1+2 thrombin fragments 1 + 2, SD standard deviation, SFMC soluble fibrin monome
aPredoseThe results of STARS E-3 (TKA) [5] and STARS J-V
(THA) [6] followed the same pattern as the pooled re-
sults reported here, with an incidence of VTE after sur-
gery of 7.4 and 2.4% for edoxaban and 13.9 and 6.9% for
enoxaparin in the 2 trials, respectively, and no significant
differences in bleeding events. In a phase 2, dose-finding
study in Japan, mean levels of D-dimer and F1+2 in-
creased after TKA and remained above baseline for 11
to 14 days in placebo-treated patients, whereas treat-
ment with edoxaban after surgery significantly reduced
levels of the coagulation biomarkers in a dose-
dependent manner [20]. In a retrospective study of
patients undergoing TKA in Japan, patients treated with
edoxaban 15 mg once daily showed significant reduc-
tions in D-dimer relative to enoxaparin 20 mg twicevarious time points after total knee or total hip arthroplasty in
t Day 7a End of treatment (days 11–14)a
n (SD) n Mean (SD) n Mean (SD)
(12.54) 521 4.40 (2.09) 511 5.35 (2.49)
8 (14.82) 443 5.38 (2.32) 430 6.00 (2.96)
.6 (748.6) 521 361.5 (164.6) 511 293.5 (169.3)
.6 (3357.3) 443 457.9 (183.8) 430 372.6 (166.6)
1 (39.32) 521 5.55 (9.04) 511 6.31 (11.22)
7 (43.53) 443 6.22 (11.68) 430 6.94 (10.80)
(9.17) 24 4.56 (1.52) 23 5.46 (2.88)
6 (24.17) 47 7.06 (3.86) 49 8.41 (3.78)
.3 (220.5) 24 352.9 (128.3) 23 248.7 (86.31)
.8 (959.3) 47 531.2 (213.6) 49 444.5 (222.0)
9 (48.89) 24 8.10 (18.70) 23 4.77 (2.38)
7 (56.12) 47 12.31 (26.32) 49 9.85 (17.73)
r complex, VTE venous thromboembolism
Table 4 Mean plasma concentrations of coagulation biomarkers at various time points after total knee or total hip arthroplasty in
patients with and without major or clinically relevant nonmajor bleeding
Preoperation Pretreatment Day 7a End of treatment (days 11–14)a
n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD)
Patients without major or CRNM bleeding
D-dimer (μg/mL) Edoxaban 627 0.75 (0.99) 627 9.75 (12.95) 597 4.43 (2.07) 578 5.38 (2.49)
Enoxaparin 626 0.78 (0.92) 626 10.72 (15.39) 552 5.47 (2.53) 517 6.15 (3.00)
F1+2 (pmol/L) Edoxaban 627 275.4 (148.0) 627 484.7 (736.0) 597 361.1 (162.2) 578 291.7 (163.2)
Enoxaparin 626 276.4 (153.3) 626 617.3 (2975.3) 552 463.4 (192.4) 517 378.2 (171.4)
SFMC (μg/mL) Edoxaban 627 5.72 (17.49) 627 32.69 (40.46) 597 5.66 (9.50) 578 6.30 (11.18)
Enoxaparin 626 4.80 (8.14) 626 34.71 (45.40) 552 6.88 (13.49) 517 7.12 (11.43)
Patients with major or CRNM bleeding
D-dimer (μg/mL) Edoxaban 30 0.52 (0.27) 30 8.73 (11.84) 15 4.53 (1.70) 9 6.29 (3.52)
Enoxaparin 24 0.89 (1.29) 24 8.95 (9.28) 14 5.24 (1.86) 10 8.40 (6.20)
F1+2 (pmol/L) Edoxaban 30 264.5 (108.3) 30 440.3 (430.4) 15 371.5 (141.5) 9 325.0 (140.9)
Enoxaparin 24 265.8 (113.4) 24 526.2 (714.4) 14 470.3 (143.3) 10 449.0 (120.6)
SFMC (μg/mL) Edoxaban 30 3.41 (1.82) 30 30.28 (44.24) 15 4.03 (1.06) 9 6.42 (3.20)
Enoxaparin 24 5.05 (4.38) 24 26.66 (32.86) 14 4.08 (1.49) 10 7.84 (4.31)
CNRM clinically relevant nonmajor, F1+2 thrombin fragments 1 + 2, SD standard deviation, SFMC soluble fibrin monomer complex
aPredose
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period following surgery [21].
Edoxaban directly and selectively inhibits FXa, which
is part of both the intrinsic and extrinsic coagulation
pathways that lead to generation of thrombin and clot
formation [22, 23]. One molecule of FXa can catalyze
the formation of approximately 1000 thrombin mole-
cules [23]. In contrast, LMWHs target FXa indirectly
and affect multiple targets in the coagulation pathway
[23]. The direct and selective targeting of FXa by edoxa-
ban may account for the significantly greater reduction
in coagulation biomarkers, which translates to reduced
rates of VTE.
Limitations of this analysis include that it is post hoc
and that it combines data from 2 different studies. How-
ever, the studies were very similar in anticoagulantFig. 4 Incidence of major and CRNM bleeding events. aChi square
test; CI = confidence interval; CRNM = clinically relevant nonmajortreatment regimens and patient characteristics. In
addition, for the coagulation biomarker results, pooling
of results was required to obtain sufficient data to per-
form statistical comparisons between treatments. It also
should be noted that edoxaban is approved only in Japan
for VTE prophylaxis and is not approved for this indica-
tion in Europe or the United States.Conclusions
In conclusion, the biomarker results for the pooled ana-
lysis of the TKA and THA trials may suggest stronger
anticoagulant activity with once-daily oral edoxaban
30 mg than twice-daily, subcutaneous enoxaparin 20 mg
following lower limb orthopedic surgery, although the
initial timing of edoxaban or enoxaparin administration
differed. The 2 treatments were associated with similar
rates of bleeding events.Additional file
Additional file 1: Table S1. Median and range of plasma concentrations
of coagulation biomarkers at various time points after total knee or total hip
arthroplasty. (DOCX 14 kb)Abbreviations
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